JP7328151B2 - Ｈｅｒ２陽性がんの処置 - Google Patents

Ｈｅｒ２陽性がんの処置 Download PDF

Info

Publication number
JP7328151B2
JP7328151B2 JP2019558369A JP2019558369A JP7328151B2 JP 7328151 B2 JP7328151 B2 JP 7328151B2 JP 2019558369 A JP2019558369 A JP 2019558369A JP 2019558369 A JP2019558369 A JP 2019558369A JP 7328151 B2 JP7328151 B2 JP 7328151B2
Authority
JP
Japan
Prior art keywords
cancer
months
tucatinib
medicament
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019558369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517696A (ja
JP2020517696A5 (enExample
Inventor
スコット ピーターソン
ルーク ウォーカー
Original Assignee
シージェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージェン インコーポレイテッド filed Critical シージェン インコーポレイテッド
Publication of JP2020517696A publication Critical patent/JP2020517696A/ja
Publication of JP2020517696A5 publication Critical patent/JP2020517696A5/ja
Priority to JP2023126666A priority Critical patent/JP2023145689A/ja
Application granted granted Critical
Publication of JP7328151B2 publication Critical patent/JP7328151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019558369A 2017-04-28 2018-04-27 Ｈｅｒ２陽性がんの処置 Active JP7328151B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023126666A JP2023145689A (ja) 2017-04-28 2023-08-03 Ｈｅｒ２陽性がんの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491872P 2017-04-28 2017-04-28
US62/491,872 2017-04-28
PCT/US2018/029899 WO2018201016A1 (en) 2017-04-28 2018-04-27 Treatment of her2 positive cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023126666A Division JP2023145689A (ja) 2017-04-28 2023-08-03 Ｈｅｒ２陽性がんの処置

Publications (3)

Publication Number Publication Date
JP2020517696A JP2020517696A (ja) 2020-06-18
JP2020517696A5 JP2020517696A5 (enExample) 2021-09-09
JP7328151B2 true JP7328151B2 (ja) 2023-08-16

Family

ID=62165692

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558369A Active JP7328151B2 (ja) 2017-04-28 2018-04-27 Ｈｅｒ２陽性がんの処置
JP2023126666A Pending JP2023145689A (ja) 2017-04-28 2023-08-03 Ｈｅｒ２陽性がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023126666A Pending JP2023145689A (ja) 2017-04-28 2023-08-03 Ｈｅｒ２陽性がんの処置

Country Status (13)

Country Link
US (3) US11207324B2 (enExample)
EP (1) EP3615067A1 (enExample)
JP (2) JP7328151B2 (enExample)
KR (1) KR102845148B1 (enExample)
CN (1) CN111032082B (enExample)
AU (2) AU2018258663B2 (enExample)
BR (1) BR112019022280A2 (enExample)
CA (1) CA3060407A1 (enExample)
EA (1) EA201992573A1 (enExample)
MA (1) MA49059A (enExample)
SG (1) SG11201909676WA (enExample)
WO (1) WO2018201016A1 (enExample)
ZA (1) ZA201907225B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032082B (zh) * 2017-04-28 2025-01-07 西雅图基因公司 Her2阳性癌症的治疗
TW202042820A (zh) * 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
WO2020251556A1 (en) * 2019-06-11 2020-12-17 Io Therapeutics, Inc. Use of an rxr agonist in treating her2+ cancers
KR20220086627A (ko) * 2019-10-21 2022-06-23 시아겐 인크. 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법
US20220387618A1 (en) * 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
IL298538A (en) * 2020-05-29 2023-01-01 Seagen Inc Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
WO2022026510A1 (en) * 2020-07-29 2022-02-03 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
US20230372342A1 (en) * 2020-09-28 2023-11-23 Seagen Inc. Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images
WO2024183622A1 (zh) * 2023-03-03 2024-09-12 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2025132522A1 (en) 2023-12-20 2025-06-26 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US20100063074A1 (en) 2004-06-03 2010-03-11 Berger Mark S Cancer Treatment Method
DK1971601T3 (da) 2005-11-15 2010-02-08 Array Biopharma Inc N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme
WO2009042618A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
MY166445A (en) 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
NO2719708T3 (enExample) * 2009-11-13 2018-03-24
SG194609A1 (en) * 2011-05-19 2013-12-30 Lab Corp America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
WO2013056108A2 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
KR102490961B1 (ko) 2012-03-23 2023-01-19 어레이 바이오파마 인크. 뇌암의 치료
WO2016011328A1 (en) * 2014-07-17 2016-01-21 Baker Cheryl Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
US10702527B2 (en) * 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN109952306A (zh) * 2016-04-19 2019-06-28 加利福尼亚大学董事会 ErbB抑制剂及其用途
CN111032082B (zh) 2017-04-28 2025-01-07 西雅图基因公司 Her2阳性癌症的治疗
US20210239702A1 (en) 2018-06-14 2021-08-05 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
TW202042820A (zh) 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
KR20220086627A (ko) 2019-10-21 2022-06-23 시아겐 인크. 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
MX2022011160A (es) 2020-03-11 2022-10-18 Seagen Inc Metodos de tratar canceres mutantes de her2 con tucatinib.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research，2017年，Vol.77,No.4,Supp. Supplement 1.，Abstract Number: P4-21-01

Also Published As

Publication number Publication date
MA49059A (fr) 2021-03-24
JP2020517696A (ja) 2020-06-18
KR102845148B1 (ko) 2025-08-20
SG11201909676WA (en) 2019-11-28
US11666572B2 (en) 2023-06-06
CA3060407A1 (en) 2018-11-01
CN111032082B (zh) 2025-01-07
US20200188401A1 (en) 2020-06-18
BR112019022280A2 (pt) 2020-05-19
AU2018258663A1 (en) 2019-11-14
ZA201907225B (en) 2023-11-29
AU2022241509A1 (en) 2022-10-27
US12048698B2 (en) 2024-07-30
WO2018201016A1 (en) 2018-11-01
US20220168303A1 (en) 2022-06-02
JP2023145689A (ja) 2023-10-11
EA201992573A1 (ru) 2020-04-06
US20230390290A1 (en) 2023-12-07
AU2022241509B2 (en) 2025-02-20
EP3615067A1 (en) 2020-03-04
US11207324B2 (en) 2021-12-28
AU2018258663B2 (en) 2022-08-04
CN111032082A (zh) 2020-04-17
KR20200014298A (ko) 2020-02-10

Similar Documents

Publication Publication Date Title
JP7328151B2 (ja) Ｈｅｒ２陽性がんの処置
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
CN104519887A (zh) 包含B-Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
UA125436C2 (uk) Фармацевтичні комбінації
TW202133857A (zh) 用於乳癌治療之組合療法
JP2012524087A (ja) 抗ｅｇｆｒ物質とｉｇｆ−１ｒ特異的インヒビターとを使用する組合せ療法
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
KR20230078705A (ko) 항-her2 항체와 병용된 투카티닙으로 her2 변형에 의해 유도된 고형 종양을 치료하는 방법
JP2008501006A (ja) Ｓｒｃキナーゼ阻害剤ＡＺＤ０５３０、および、抗エストロゲン剤またはＥＧＦＲ−ＴＫ−阻害剤を含む組み合わせ製品
WO2022111618A1 (zh) 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物
TW202224682A (zh) 用於治療實性瘤之方法與包含ｋｒａｓｇ１２ｃ抑制劑及ｖｅｇｆ抑制劑之組成物
JP2023537676A (ja) トラスツズマブ、タキサン及びｖｅｇｆｒ－２アンタゴニストと組み合わせたツカチニブによりｈｅｒ２陽性癌を治療する方法
CN112915202B (zh) 喹啉衍生物与pd-1单抗的药物组合
TW202320790A (zh) 治療癌症之方法
EA044960B1 (ru) Лечение her2-положительных злокачественных новообразований
HK40076724A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
WO2023230429A1 (en) Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
WO2021088853A1 (zh) 喹啉衍生物与pd-1单抗的药物组合
TW201302792A (zh) 組合抗ｅｒｂｂ３抗體及酪胺酸激酶抑制劑的劑量及投藥

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

TRDD Decision of grant or rejection written
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230803

R150 Certificate of patent or registration of utility model

Ref document number: 7328151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150